Lyn Baranowski

Lyn Baranowski

Director Ejecutivo en Avalyn Pharma, Inc. .

Health Technology
Consumer Services
Finance

Perfil

Lyn Baranowski is currently the Chief Executive Officer & Director at Avalyn Pharma, Inc. and a Director at Rani Therapeutics LLC.
Previously, Lyn held positions as a Director at Novartis Pharmaceuticals Corp., an Independent Director at Rani Therapeutics Holdings, Inc., Senior VP-Corporate Development & Strategy at Melinta Subsidiary Corp., Vice President-Commercial Development at Pearl Therapeutics, Inc., Vice President at Vatera Healthcare Partners, Senior VP-Corporate Development & Strategy at Melinta Therapeutics, Inc., and Chief Operating Officer at Altavant Sciences, Inc. Lyn obtained an undergraduate degree from American University and an MBA from Harvard Business School.

Cargos activos de Lyn Baranowski

EmpresasCargoInicio
Director/Miembro de la Junta -
Director Ejecutivo 14/10/2022
Todos los cargos activos de Lyn Baranowski

Antiguos cargos conocidos de Lyn Baranowski.

EmpresasCargoFin
RANI THERAPEUTICS HOLDINGS, INC. Director/Miembro de la Junta 02/05/2023
MELINTA THERAPEUTICS, INC. Corporate Officer/Principal 01/07/2018
Director de Operaciones -
Director/Miembro de la Junta -
Corporate Officer/Principal -
Ver el detalle de la experiencia de Lyn Baranowski.

Formación de Lyn Baranowski.

American University Undergraduate Degree
Harvard Business School Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Lyn Baranowski.

Relaciones

38

Relaciones de 1er grado

11

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas1
RANI THERAPEUTICS HOLDINGS, INC.

Health Technology

Empresas privadas8

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Ver las conexiones de la empresa
-40% Oferta por Tiempo Limitado: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA